Effect of monthly minodronate after switching from raloxifene hydrochloride for the treatment of postmenopausal osteoporosis in women with loss of ovarian function due to gynecologic malignancies
Not Applicable
Completed
- Conditions
- Osteoporosis
- Registration Number
- JPRN-UMIN000013916
- Lead Sponsor
- Osaka University Graduate School of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- Female
- Target Recruitment
- 50
Inclusion Criteria
Not provided
Exclusion Criteria
Patients are excluded if being 1. with concomitant use of other agents for osteoporosis 2. with concomitant use of other agents, which potentially affect bone turnover 3. with esophageal stricture or achalasia 4. unable to remain upright for 30 min after dosing 5. with hypersensitivity to minodronate or other bisphosphonates 6. with hypocalcaemia 7. with aphagia, esophagitis, gastritis, duodenitis, or ulcers 8. with severe nephropathy 9. inappropriate to participate in the study
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Hip BMD or lumber BMD Bone turnover markers (serum type I collagen cross-linked N-telopeptide)
- Secondary Outcome Measures
Name Time Method